Calliditas Therapeutics: Undervalued Rare Disease Commercial Stage Biotech (CALT)
ljubaphoto/E+ via Getty Images Background In our previous post-Q2 2023 earnings note, we maintained a buy rating on Calliditas Therapeutics AB (publ) (NASDAQ:CALT) based on two key theses: a) the sales ramp of Tarpeyo accelerating in 2024 with the label expansion and improvement in market access, and b) label expansion around disease modifying claim and…